A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 819,968 shares of NBIX stock, worth $104 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
819,968
Previous 782,870 4.74%
Holding current value
$104 Million
Previous $108 Million 12.34%
% of portfolio
0.23%
Previous 0.28%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$114.58 - $153.15 $4.25 Million - $5.68 Million
37,098 Added 4.74%
819,968 $94.5 Million
Q2 2024

Jul 29, 2024

SELL
$130.86 - $143.19 $958,287 - $1.05 Million
-7,323 Reduced 0.93%
782,870 $108 Million
Q1 2024

May 08, 2024

BUY
$130.4 - $143.74 $9.08 Million - $10 Million
69,600 Added 9.66%
790,193 $109 Million
Q4 2023

Feb 09, 2024

BUY
$106.07 - $132.76 $4.48 Million - $5.61 Million
42,263 Added 6.23%
720,593 $94.9 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $2 Million - $2.5 Million
21,308 Added 3.24%
678,330 $76.3 Million
Q2 2023

Aug 08, 2023

BUY
$89.53 - $104.87 $3.97 Million - $4.65 Million
44,368 Added 7.24%
657,022 $62 Million
Q1 2023

May 08, 2023

BUY
$94.11 - $123.02 $5.77 Million - $7.54 Million
61,297 Added 11.12%
612,654 $62 Million
Q4 2022

Feb 09, 2023

BUY
$106.72 - $127.06 $1.91 Million - $2.27 Million
17,851 Added 3.35%
551,357 $65.9 Million
Q3 2022

Nov 10, 2022

BUY
$92.03 - $107.81 $7.89 Million - $9.24 Million
85,689 Added 19.13%
533,506 $56.7 Million
Q2 2022

Aug 04, 2022

BUY
$75.79 - $100.07 $6.73 Million - $8.89 Million
88,840 Added 24.75%
447,817 $43.7 Million
Q1 2022

May 12, 2022

SELL
$72.45 - $94.81 $986,406 - $1.29 Million
-13,615 Reduced 3.65%
358,977 $33.7 Million
Q4 2021

Feb 09, 2022

SELL
$79.65 - $106.22 $1.53 Million - $2.03 Million
-19,158 Reduced 4.89%
372,592 $31.7 Million
Q3 2021

Nov 08, 2021

SELL
$86.18 - $99.03 $102,726 - $118,043
-1,192 Reduced 0.3%
391,750 $37.6 Million
Q2 2021

Aug 05, 2021

BUY
$89.43 - $102.27 $6.21 Million - $7.11 Million
69,482 Added 21.48%
392,942 $38.2 Million
Q1 2021

May 05, 2021

BUY
$87.57 - $119.4 $5.73 Million - $7.81 Million
65,431 Added 25.36%
323,460 $31.5 Million
Q4 2020

Feb 12, 2021

SELL
$86.91 - $108.33 $509,900 - $635,572
-5,867 Reduced 2.22%
258,029 $24.7 Million
Q3 2020

Nov 09, 2020

BUY
$96.16 - $135.15 $4.09 Million - $5.75 Million
42,543 Added 19.22%
263,896 $25.4 Million
Q2 2020

Aug 04, 2020

SELL
$85.09 - $130.36 $1.24 Million - $1.89 Million
-14,531 Reduced 6.16%
221,353 $27 Million
Q1 2020

May 12, 2020

BUY
$75.11 - $113.76 $2.48 Million - $3.75 Million
32,994 Added 16.26%
235,884 $20.4 Million
Q4 2019

Feb 11, 2020

SELL
$86.8 - $118.57 $8.26 Million - $11.3 Million
-95,184 Reduced 31.93%
202,890 $21.8 Million
Q3 2019

Nov 12, 2019

SELL
$83.82 - $101.5 $8.95 Million - $10.8 Million
-106,738 Reduced 26.37%
298,074 $26.9 Million
Q2 2019

Aug 02, 2019

BUY
$72.24 - $91.27 $2.74 Million - $3.46 Million
37,933 Added 10.34%
404,812 $34.2 Million
Q1 2019

Apr 26, 2019

BUY
$69.31 - $91.53 $12.9 Million - $17 Million
186,150 Added 103.0%
366,879 $32.3 Million
Q4 2018

Feb 13, 2019

SELL
$68.32 - $124.36 $800,915 - $1.46 Million
-11,723 Reduced 6.09%
180,729 $12.4 Million
Q3 2018

Nov 13, 2018

SELL
$98.88 - $125.85 $5.31 Million - $6.76 Million
-53,695 Reduced 21.81%
192,452 $23.7 Million
Q2 2018

Aug 01, 2018

BUY
$75.3 - $105.99 $10.3 Million - $14.5 Million
136,401 Added 124.29%
246,147 $24.2 Million
Q1 2018

May 07, 2018

SELL
$75.88 - $92.43 $10.7 Million - $13.1 Million
-141,453 Reduced 56.31%
109,746 $9.1 Million
Q4 2017

Feb 01, 2018

SELL
$58.53 - $77.59 $15.9 Million - $21.1 Million
-271,602 Reduced 51.95%
251,199 $19.5 Million
Q3 2017

Nov 02, 2017

BUY
$47.97 - $61.28 $25.1 Million - $32 Million
522,801
522,801 $32 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Bnp Paribas Asset Management Holding S.A. Portfolio

Follow Bnp Paribas Asset Management Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bnp Paribas Asset Management Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Bnp Paribas Asset Management Holding S.A. with notifications on news.